Phase 3 trial shows lurbinectedin plus atezolizumab significantly improves progression-free and overall survival in ES-SCLC ...

A new study is the first phase 3 to show meaningful improvement in both progression-free and overall survival with first-line ...

The University of Virginia Medical Center is not just one of Newsweek’s top 50 hospitals in the country (and No. 1 in the ...

The latest news from ASCO 2025 focusing on SCLC including abstracts, features, and helpful conference information.

PFS in Phase 3 HARMONi study was met with statistical significance, but OS was not. Click here to find out why SMMT stock is ...

Jazz Pharma and PharmaMar have revealed the overall survival (OS) data for their chemotherapy drug Zepzelca in ...

Patients with extensive-stage small cell lung cancer (SCLC) experienced clinically meaningful benefits with lurbinectedin ...

Debiopharm ( a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure ...

SCLC, first-line maintenance therapy with Zepzelca plus Tecentriq led to improvements in PFS and OS versus Tecentriq alone.

Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to ...

Roche’s plan to bolster Tecentriq’s position in small cell lung cancer with Jazz Pharmaceuticals’ Zepzelca has paid off. | ...